颅内恶性肿瘤体外化疗敏感试验的临床应用观察

目的研究颅内肿瘤组织标本体外化疗药物敏感性与临床疗效的关系,为颅内恶性肿瘤病人个体化化疗提供依据。方法将新鲜的41例恶性颅内肿瘤组织标本应用MTT法进行7种脑肿瘤常用化疗药物以及与尼莫通(NIM)联合的体外敏感性测定,经筛选后将敏感药物经静脉或颈内动脉超选择应用。结果41例颅内恶性肿瘤病理标本对7种化疗药物总体上较为敏感,其单独药物敏感顺序依次为卡氮芥(BCNU)、威猛(VM-26)、甲氨喋呤(MTX)、顺铂(DDP)、足叶乙甙(VP-16)、长春新碱(VCR)、阿霉素(ADM),与NIM联合药物的抑制率顺序依次为BCNU、VM-26、VP-16、DDP、ADM、VCR。药物治疗随访观察,1年以上存活71.9%(23/32),2年以上存活56.3%(18/32)。结论常规脑肿瘤化疗药物对不同个体敏感程度不一,因此,体外化疗药物敏感试验可帮助临床医生制定合理的化疗方案,按其结果指导化疗可能有助于提高颅内恶性肿瘤病人的远期存活率。

CLINICAL STUDY ON IN VITRO CHEMOTHERAPY SENSITIVITY TEST OF INTRACRANIAL MALIGNANT TUMORS

ObjectiveTo provide a guidance for individual chemotherapy in patients with intracranial malignant tumors by studying the relativity of chemosensitivity of anti-tumor drugs.MethodsThe chemosensitivity of seven kinds of anti-tumor drugs and their combination with nimodipine were tested,in vitro,in 41 intracranial malignant tumors by MTT method.Results(The seven) drugs for the tumors were carmustine,VM-26,methotrexate,cisplatin,VP-16,vincristin and adriamycin,which associated with nimodipine was carmustine,VM-26,VP-16,cisplatin,adriamycin,and vincristin.The one-year survival was 71.9%(23/32),and two-year survival,56.3%(18/32).ConclusionThe chemotherapy sensitivity in patients with intracranial malignant tumors is different.Chemotherapy under the guidance of chemosensitivity in vitro may establish reasonable methods and improve long-term survival of patients with intracranial malignant tumors.